参考文献/References:
1 Van den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine:current status[J]. J Clin Oncol, 2004, 22(17):3593-3607.
2 Krenning EP, Kwekkeboom DJ, Valkema R, et al. Peptide receptor radionuclide therapy[J]. Ann NY Acad Sci, 2004, 1014:234-245.
3 Boerman OC, Oyen WJ, Corstens FH. Radio-labeled receptor binding peptides:a new class of radiopharmaceutical[J]. Semin Nucl Med,2000, 30(3):195-208.
4 Meko JB, Doherty GM, Siegel BA, et al. Evaluation of somatostatin receptor scintigraphy for detecting neuroendocrine tumors[J]. Surgery,1996, 120(6):975-984.
5 Marcos HB, Libutti SK, Alexander HR, et al. Neuroendocrine tumors of the pancreas in yon Hippel-Lindau disease; spectrum of appearance at CT and MR imaging of with histopathologic comparison[J].Radiology, 2002, 225(3):751-758.
6 Bombardieri E, Chiti A, Crippa F, et al. 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer[J]. Q J Nucl Med,1995,39(4 suppl 1):104-107.
7 Reisinger I, Bohuslavitzki KH, Brenner W, et al. Somatostatin receptor scintigraphy in small-cell lung cancer:, results of a multicenter study[J]. J Nucl Med, 1998, 39(2):224-227.
8 Nachar O, Rousseau JA, Lefebvre B, et al. Dosimetry and metabolism of 11beta-methoxy-(17alpha, 20E/Z)-[123I] iodovinylestradio in healthy women and breast cancer patients[J]. J Nucl Med, 1999, 40(10):1728-1736.
9 Pallela VR, Thakur ML, Chakder S, et al. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans[J]. J Nucl Med, 2000, 41(1):107-110.
10 Rao PS, Thakur ML, Pallela V, et al. 99mTc labeled VIP analog:evaluation for imaging colorectal cancer[J]. Nucl Med Biol, 2001, 28(4):445-450.
11 Thakur ML, Aruva MR, Gariepy J, et al. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog:comparison with 99mTc-VIP analog[J]. J Nucl Med, 2004, 45(8):1381-1389.
12 Sueyoshi K, Narabayashi I, Aratani T, et al. Utility of Tc-99m GSA wholebodyscintigraphy in detecting bone metastases from hepatocellular carcinoma[J]. Clin Nucl Med, 2001, 26(3):221-224.
13 Becherer A, Szabo M, Karanikas G, et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET[J]. J Nucl Med, 2004,45(7):1161-1167.
14 Shaul M, Abourbeh G, Jacobson O, et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging incancer[J]. Bioorg Med Chem, 2004, 12(13):3421-3429.
15 Li H, Zhang Z, Blessington D, et al. Carbocyanine labeled LDL for optical imaging of tumors[J]. Acad Radiol, 2004, 11(6):669-677.
16 Chen X, Park R, Hou Y, et al. Micro PET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3] bombesin in human prostate adenocarcinoma xenografts[J]. J Nucl Med, 2004,45(8):1390-1397.
17 Otte A, Herrmann R, Heppeler A, et al. Yttium-90 DOTA-TOC:first clinical results[J]. Eur J Nucl Med, 1999, 26(11):1439-1447.
18 DE-Jong M, Breeman WA, Bernard BF, et al.[177Lu-DOTA(0),Tyr3] octreotide for somatostatin receptor-targeted therapy[J]. Int J Cancer, 2001, 92(5):628-633.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[3]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[4]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[5]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[6]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[7]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[8]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[9]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[10]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[11]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[12]杨明福,李前伟.肿瘤血管内皮生长因子受体核素显像研究现状[J].国际放射医学核医学杂志,2010,34(1):19.[doi:10.3760/cma.j.issn.1673-4114.2010.01.005]
YANG Ming-fu,LI Qian-wei.Review present study on vascular endothelial growth factor receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):19.[doi:10.3760/cma.j.issn.1673-4114.2010.01.005]
[13]高玉婷,王自正.生长抑素类似物介导靶向显像及治疗的研究现状和进展[J].国际放射医学核医学杂志,2009,33(6):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
GAO Yu-ting,WANG Zi-zheng.The development of somatostatin analogues mediated tumor targeting and therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
[14]汪永红,陈文新,何品玉.肿瘤表皮生长因子受体的分子显像研究[J].国际放射医学核医学杂志,2009,33(4):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
WANG Yong-hong,CHEN Wen-xin,HE Pin-yu.Tumor epidermal growth factor receptor molecular imaging research[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
[15]郑玉民,王自正,王峰,等.以表皮生长因子受体为靶点的肿瘤分子靶向治疗[J].国际放射医学核医学杂志,2007,31(1):21.
ZHENG Yu-min,WANG Zi-zheng,WANG Feng,et al.Epidermal growth factor receptor targeted molecularly therapies of cancers[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):21.
[16]王秀娟,李险峰.生长抑素受体肿瘤显像的临床应用及研究进展[J].国际放射医学核医学杂志,2006,30(4):217.
WANG Xiu-juan,LI Xian-feng.Clinical application and progress of somatostatin receptor imaging in diagnosis of cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):217.
[17]郑建国,谭天秩.放射性核素反义治疗在恶性肿瘤中的应用[J].国际放射医学核医学杂志,1998,22(6):242.